ASX Announcements


 
10 Jan 2025    Notice under s708A(12C)(e) of the Corporations Act 2001  
 
10 Jan 2025    Notification regarding unquoted securities - NOX  
 
10 Jan 2025    Notification regarding unquoted securities - NOX  
 
18 Dec 2024    Convertible Note update  
 
16 Dec 2024    Change of Director's Interest Notice - BP  
 
16 Dec 2024    Notification of cessation of securities - NOX  
 
4 Dec 2024    Contract Research Organisation signed for HERACLES trial  
 
19 Nov 2024    Results of Meeting  
 
19 Nov 2024    Noxopharm 2024 AGM Corporate Presentation  
 
19 Nov 2024    Noxopharm 2024 AGM Chair Address  
 
12 Nov 2024    Noxopharm enhances 2024 cash position via R&D rebate  
 
6 Nov 2024    Notification of cessation of securities - NOX  
 
5 Nov 2024    Proposed issue of securities - NOX  
 
5 Nov 2024    Additional convertible note for long-term shareholder  
 
29 Oct 2024    September 2024 Quarterly Activities report and Appendix 4C  
 
25 Oct 2024    2024 AGM Addendum to the Notice of Meeting and Proxy  
 
14 Oct 2024    Minor correction to funding announcement  
 
14 Oct 2024    AGM Letter of Access, Notice of Meeting and Proxy  
 
11 Oct 2024    Unlisted Options Upcoming Expiry  
 
10 Oct 2024    SOF-SKN manufacturer signed for HERACLES clinical trial  
 
30 Sep 2024    Annual Report to shareholders  
 
27 Sep 2024    Audited Financial Statements  
 
27 Sep 2024    Appendix 4G and Corporate Governance Statement  
 
27 Sep 2024    Proposed issue of securities - NOX  
 
27 Sep 2024    New funding from sophisticated investors  
 
17 Sep 2024    Noxopharm completes SOF-SKN formulation as clinical trial approaches  
 
6 Sep 2024    Advanced funding secured ahead of R&D rebate  
 
3 Sep 2024    Significant results from new brain cancer drugs  
 
30 Aug 2024    Ceasing to be a substantial holder - Goodridge  
 
29 Aug 2024    Appendix 4E Preliminary Final Report  
 
19 Aug 2024    Noxopharm Targets Clinical Trial for First-in-Class Drug  
 
14 Aug 2024    Significant CRO-67 Results in Pancreatic Cancer Studies  
 
23 Jul 2024    June 2024 Quarterly Activities Report and Appendix 4C  
 
28 May 2024    Noxopharm joins global Alliance for mRNA Medicines  
 
14 May 2024    Milestone reached as SOF-SKN progresses to next level  
 
29 Apr 2024    March 2024 Quarterly Activities Report and Appendix 4C  
 
4 Apr 2024    Tour de Cure Grant for Brain Cancer Research  
 
27 Feb 2024    Appendix 4D and Half Year 2024 Financial Report  
 
13 Feb 2024    Noxopharm extends Hudson Institute strategic partnership  
 
22 Jan 2024    December 2023 Quarterly Activities Report and Appendix 4C  
 
18 Dec 2023    Change of Director's Interest Notice - GM  
 
18 Dec 2023    Notification of cessation of securities - NOX  
 
16 Nov 2023    Results of Meeting  
 
16 Nov 2023    Noxopharm Enhances Cash Position via R&D Rebate  
 
16 Nov 2023    Noxopharm 2023 AGM Corporate Presentation  
 
16 Nov 2023    Noxopharm 2023 AGM Chair Address  
 
27 Oct 2023    Unlisted Options Expiring on 16 December 2023  
 
18 Oct 2023    mRNA Vaccine Enhancer Shows Inflammation Reduction  
 
13 Oct 2023    September 2023 Activities Report and Appendix 4C  
 
9 Oct 2023    Response to ASX Query  
 
4 Oct 2023    US FDA grants Orphan Drug Designation for CRO-67  
 
3 Oct 2023    Trading Halt  
 
3 Oct 2023    Pause in Trading  
 
28 Sep 2023    Latest CRO-67 data shows success in reducing cancer growth  
 
28 Sep 2023    2023 AGM Notice of Meeting and Proxy  
 
28 Sep 2023    2023 AGM Letter to Shareholders and Proxy  
 
27 Sep 2023    Annual Report to shareholders  
 
21 Sep 2023    Change of Director's Interest Notice - FB  
 
18 Sep 2023    Change of Director's Interest Notice - FB  
 
31 Aug 2023    Appendix 4E and Audited Financial Statements  
 
31 Aug 2023    Appendix 4G and Corporate Governance Statement  
 
24 Jul 2023    Notification of cessation of securities - NOX  
 
14 Jul 2023    June 2023 Activities Report and Appendix 4C  
 
5 Jul 2023    Upcoming Expiry of Listed Options (ASX Code NOXOA)  
 
5 Jul 2023    Unlisted Options expiring on 23 July 2023  
 
5 Jul 2023    Notification of cessation of securities - NOX  
 
3 Jul 2023    Change of Director's Interest Notice - FB  
 
29 Jun 2023    Change of Director's Interest Notice - FB  
 
19 Jun 2023    Change of Director's Interest Notice - FB  
 
19 Jun 2023    Change of Director's Interest Notice - BP  
 
19 Jun 2023    Change of Director's Interest Notice - PM  
 
19 Jun 2023    Details of Company Address  
 
26 May 2023    IONIC Trial Abstract Published at ASCO  
 
19 May 2023    Study results show new Sofra drug reduces inflammation  
 
18 May 2023    Innovative Sofra research presented at European event  
 
10 May 2023    Change of Director's Interest Notice - FB  
 
8 May 2023    Upcoming Expiry of Listed Options (ASX Code NOXO)  
 
4 May 2023    Change of Director's Interest Notice - FB  
 
24 Apr 2023    March 2023 Quarterly Activities Report and Appendix 4C  
 
6 Apr 2023    Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs  
 
28 Mar 2023    Noxopharm Announces Novel mRNA Vaccine Enhancer  
 
24 Feb 2023    Appendix 4D and Half Year 2023 Financial Report  
 
22 Feb 2023    Noxopharm to Present Sofra Study at LUPUS 2023 Conference  
 
27 Jan 2023    December 2022 Quarterly Activities Report and Appendix 4C  
 
17 Jan 2023    DARRT-2 Trial Efficacy Phase to Commence  
 
16 Dec 2022    NOX Pipeline Boosted by $1.5M Grant to Hudson Institute  
 
15 Dec 2022    Change of Director's Interest Notice - FB  
 
15 Dec 2022    Notification of cessation of securities - NOX  
 
6 Dec 2022    Federal Innovation Connections Grant Awarded  
 
2 Dec 2022    IONIC Trial Progresses as Veyonda Passes Safety Milestone  
 
21 Nov 2022    Notification of cessation of securities - NOX  
 
17 Nov 2022    Constitution  
 
17 Nov 2022    Results of Meeting  
 
17 Nov 2022    Noxopharm 2022 AGM Corporate Presentation  
 
17 Nov 2022    Noxopharm AGM 2022 Chair's Address  
 
16 Nov 2022    CEP-2 Safety Milestone Shows Veyonda Progress  
 
10 Nov 2022    Noxopharm Enhances Cash Position via R&D Rebate  
 
25 Oct 2022    Change in substantial holding  
 
21 Oct 2022    September 2022 Quarterly Activities Report and Appendix 4C  
 
18 Oct 2022    2022 AGM Notice of Meeting and Proxy  
 
18 Oct 2022    2022 AGM Letter to Shareholders and Proxy  
 
7 Oct 2022    Unlisted Options Expiring on 21 November 2022  
 
26 Sep 2022    Noxopharm 2022 Annual Report  
 
20 Sep 2022    Final Director's Interest Notice - GK  
 
19 Sep 2022    Resignation of Dr Graham Kelly as Non-Executive Director  
 
14 Sep 2022    Novel Dual-cell Therapy Results in Pancreatic Cancer  
 
2 Sep 2022    Response to ASX Price Query (Correction to ASX Ticker)  
 
2 Sep 2022    Response to ASX Price Query  
 
25 Aug 2022    Appendix 4E and Audited Financial Statements  
 
25 Aug 2022    Appendix 4G and Corporate Governance Statement  
 
16 Aug 2022    Noxopharm & UNSW Pancreatic Cancer Research at US Conference  
 
9 Aug 2022    CEP-2 Trial Passes Safety Milestone  
 
2 Aug 2022    DARRT-2 Trial Safety Milestone and European Site Activated  
 
27 Jul 2022    June 2022 Quarterly Activities Report and Appendix 4C  
 
5 Jul 2022    Mayo Clinic and Washington Uni Join Noxopharm Sarcoma Trial  
 
22 Jun 2022    $1.45M Grant to Hudson Institute for Noxopharm Collaboration  
 
14 Jun 2022    Hudson Institute Collaboration Secures mRNA Victoria Acceleration Fund Grant  
 
7 Jun 2022    Noxopharm Corporate Presentation  
 
27 May 2022    Veyonda Abstract Published at ASCO Annual Meeting 2022  
 
28 Apr 2022    March 2022 Quarterly Activities Report and Appendix 4C  
 
22 Mar 2022    Orphan Drug Designation Granted to Noxopharm by US FDA  
 
28 Feb 2022    First Patient Treated in CEP-2 Sarcoma Trial  
 
21 Feb 2022    Appendix 4D and Half Year 2022 Financial Report  
 
1 Feb 2022    Initial Director's Interest Notice - GM  
 
27 Jan 2022    December 2021 Quarterly Activities Report and Appendix 4C  
 
10 Jan 2022    Noxopharm Presents at H.C. Wainwright BioConnect Conference  
 
7 Jan 2022    Noxopharm Receives A$5.865M R & D Tax Rebate  
 
5 Jan 2022    Noxopharm Announces Leadership Transition  
 
14 Dec 2021    Noxopharm DARRT-2 Cancer Trial Update  
 
2 Dec 2021    Notification of cessation of securities - NOX  
 
2 Dec 2021    Change of Director's Interest Notice - GK  
 
17 Nov 2021    Noxopharm Annual General Meeting Results  
 
17 Nov 2021    Licencing Deal Expands Noxopharm Drug Opportunities  
 
17 Nov 2021    Noxopharm 2021 AGM Corporate Presentation  
 
17 Nov 2021    Noxopharm 2021 AGM Chairmans Address  
 
16 Nov 2021    Retraction of Grant Announcement  
 
15 Nov 2021    Trading Halt  
 
15 Nov 2021    Noxopharm Awarded A$8.8M Aust Govt Grant for Sarcoma Trial  
 
4 Nov 2021    DARRT-2 Trial Commences in the U.S.  
 
29 Oct 2021    Unlisted Options Expiring on 30 November 2021  
 
26 Oct 2021    Veyonda and Opdivo IONIC Study First Patient Dosed  
 
25 Oct 2021    Patent Granted for Veyonda and Low Dose Chemotherapy  
 
20 Oct 2021    Jobkeeper s323DB Notice  
 
15 Oct 2021    2021 AGM Notice of Meeting and Proxy  
 
15 Oct 2021    2021 AGM Letter to Shareholders and Proxy  
 
14 Oct 2021    September 2021 Quarterly Activities Report and Appendix 4C  
 
29 Sep 2021    Cleansing Notice  
 
29 Sep 2021    Application for quotation of securities - NOX  
 
27 Sep 2021    Veyonda Achieves Important U.S. Patent Claims  
 
10 Sep 2021    Noxopharm 2021 Annual Report  
 
9 Sep 2021    Noxopharm Updated Corporate Presentation  
 
30 Aug 2021    Change of Registered Office and Principal Place of Business  
 
26 Aug 2021    Appendix 4E and Audited Financial Statements  
 
26 Aug 2021    Appendix 4G and Corporate Governance Statement  
 
23 Aug 2021    Cleansing Notice  
 
23 Aug 2021    Application for quotation of securities - NOX  
 
23 Aug 2021    Pre-clinical Data Supports a Role for Veyonda in COVID-19  
 
23 Aug 2021    NOXCOVID Program to Expand After Positive Phase 1 Results  
 
19 Aug 2021    Trading Halt  
 
13 Aug 2021    Cleansing Notice  
 
13 Aug 2021    Application for quotation of securities - NOX  
 
11 Aug 2021    Additional Information on US NCI Collaboration  
 
9 Aug 2021    NOX and US Govt Peak Cancer Agency Announce Collaboration  
 
5 Aug 2021    Veyonda Survival Advantage in LuPSMA Therapy Confirmed  
 
27 Jul 2021    June 2021 Quarterly Activities Report and Appendix 4C  
 
1 Jul 2021    DARRT-2 Study Receives IND Approval from FDA  
 
29 Jun 2021    Noxopharm Secures Key European Patent Allowance for Veyonda  
 
28 Jun 2021    Noxopharm Corporate Presentation  
 
21 Jun 2021    Cleansing Notice  
 
21 Jun 2021    Application for quotation of securities - NOX  
 
10 Jun 2021    DARRT-2 Study Update and Clarification  
 
8 Jun 2021    The Noxopharm Newsletter June 2021  
 
4 Jun 2021    Noxopharm Set to Benefit From Novartis ASCO Data  
 
31 May 2021    Becoming a substantial holder  
 
31 May 2021    Change of Director's Interest Notice - FB  
 
31 May 2021    Change of Director's Interest Notice - BP  
 
31 May 2021    Cleansing Notice  
 
31 May 2021    Appendix 2A  
 
31 May 2021    Appendix 3G  
 
31 May 2021    Noxopharm Extraordinary General Meeting Results  
 
31 May 2021    New Independent Trial Data Supports Potential of Veyonda  
 
13 May 2021    Noxopharm to Present to Share Cafe Hidden Gems Webinar  
 
12 May 2021    NOXCOVID Trial Achieves Full Enrolment  
 
7 May 2021    Cleansing Notice  
 
7 May 2021    Appendix 2A  
 
7 May 2021    Veyonda FDA Approved Trial to Commence  
 
4 May 2021    Securities Trading Policy  
 
30 Apr 2021    Cleansing Notice  
 
30 Apr 2021    Appendix 2A  
 
30 Apr 2021    Change of Director's Interest Notice - BP  
 
30 Apr 2021    Lapsing of Unlisted Options  
 
30 Apr 2021    Publications Positive Review of Veyonda in Chemotherapy  
 
29 Apr 2021    Notice of General Meeting/Proxy Form  
 
27 Apr 2021    March Quarterly Activities Report and Appendix 4C  
 
22 Apr 2021    Veyonda Showing Potential to Prevent Cytokine Storm  
 
22 Apr 2021    Pause in Trading  
 
12 Apr 2021    Cleansing Notice  
 
12 Apr 2021    Appendix 2A  
 
6 Apr 2021    Veyonda Patent Lodged for Major Septic Shock Opportunity  
 
29 Mar 2021    Corporate Presentation for Switzer Virtual Investor Day  
 
19 Mar 2021    Noxopharm IONIC Immuno-Oncology Trial Commences  
 
16 Mar 2021    ASX Small-Mid Cap Conference Corporate Presentation  
 
8 Mar 2021    NOXCOVID Trial Advances to Final Stage  
 
5 Mar 2021    Noxopharm Presents to H.C. Wainwright Global Conference  
 
4 Mar 2021    Cleansing Notice  
 
4 Mar 2021    Appendix 2A  
 
2 Mar 2021    Noxopharm Receives A$4.59M Federal Gov R&D Tax Rebate  
 
1 Mar 2021    Proposed issue of Securities - NOX  
 
1 Mar 2021    Lapsing of Unlisted Options and Shortfall Shares  
 
1 Mar 2021    Change of Director's Interest Notice - PM  
 
26 Feb 2021    Change in substantial holding  
 
26 Feb 2021    Change of Director's Interest Notice - GK  
 
26 Feb 2021    Cleansing Notice  
 
26 Feb 2021    Appendix 2A  
 
24 Feb 2021    Company Announcement Regarding Appendix 3Y Disclosures  
 
24 Feb 2021    Change in substantial holding  
 
24 Feb 2021    Change of Director's Interest Notice - GK  
 
23 Feb 2021    Noxopharm Updated Corporate Presentation February-March 2021  
 
19 Feb 2021    Option Underwriting Agreement to Secure Funds  
 
19 Feb 2021    Cleansing Notice  
 
19 Feb 2021    Appendix 2A  
 
16 Feb 2021    Noxopharm CEO Letter to Shareholders February 2021  
 
16 Feb 2021    Appendix 4D and Half Year Financial Report  
 
15 Feb 2021    Cleansing Notice  
 
15 Feb 2021    Appendix 2A  
 
15 Feb 2021    LuPIN Survival Outcome Confirmed by Conference Presentation  
 
9 Feb 2021    Major Survival Benefit in Prostate Cancer Patients Announced  
 
5 Feb 2021    Cleansing Notice  
 
5 Feb 2021    Appendix 2A  
 
3 Feb 2021    Cleansing Notice  
 
3 Feb 2021    Appendix 2A  
 
28 Jan 2021    Noxopharm To Present to ShareCafe Hidden Gems Webinar  
 
25 Jan 2021    Noxopharm Dec 2020 Quarterly Activities Report & Appendix 4C  
 
22 Jan 2021    Cleansing Notice  
 
22 Jan 2021    Appendix 2A  
 
13 Jan 2021    NOXCOVID Study Advances  
 
12 Jan 2021    Unlisted Options Expiring 28 February 2021  
 
6 Jan 2021    Noxopharm Shareholder Update 2021  
 
23 Dec 2020    Federal Government Approved Future Overseas R&D Expenditure  
 
15 Dec 2020    Cleansing Notice  
 
15 Dec 2020    Appendix 2A  
 
15 Dec 2020    Change of Director's Interest Notice - BP  
 
15 Dec 2020    Change of Director's Interest Notice - FB  
 
15 Dec 2020    Appendix 3G  
 
11 Dec 2020    December Investor Webinar Recording  
 
10 Dec 2020    Change in substantial holding  
 
10 Dec 2020    Cleansing Notice  
 
10 Dec 2020    Appendix 2A  
 
8 Dec 2020    Noxopharm Corporate Presentation December Investor Webinar  
 
7 Dec 2020    Pre-Clinical Breakthrough Discovery Set to Expand Pipeline  
 
4 Dec 2020    Noxopharm December Investor Webinar Details  
 
3 Dec 2020    Cleansing Statement  
 
3 Dec 2020    Proposed issue of Securities - NOX  
 
3 Dec 2020    Noxopharm Completes A$23m Placement to Fund Clinical Studies  
 
1 Dec 2020    Appendix 2A  
 
1 Dec 2020    Trading Halt  
 
27 Nov 2020    Change of Director's Interest Notice - PM  
 
27 Nov 2020    Lapsing of Unlisted Options  
 
18 Nov 2020    Change of Director's Interest Notice - GK  
 
18 Nov 2020    Cleansing Notice  
 
18 Nov 2020    Appendix 2A  
 
18 Nov 2020    Appendix 3G  
 
18 Nov 2020    Further Independent Support for Veyonda as a Major I-O Drug  
 
17 Nov 2020    Noxopharm Annual General Meeting Results  
 
17 Nov 2020    Noxopharm 2020 AGM Corporate Update  
 
17 Nov 2020    2020 AGM Chairman's Address  
 
13 Nov 2020    Independent Discovery Validates DARRT Cancer Therapy  
 
9 Nov 2020    Veyonda To Be Tested In Combination With Opdivo In Trial  
 
5 Nov 2020    Dedicated Septic Shock Company Established  
 
5 Nov 2020    NOXCOVID Study Cleared To Expand  
 
3 Nov 2020    2020 Annual General Meeting Reminder  
 
26 Oct 2020    Cleansing Notice  
 
26 Oct 2020    Appendix 2A  
 
26 Oct 2020    First Two Cohorts Enrolled in NOXCOVID Study  
 
15 Oct 2020    Noxopharm September 2020 Quarterly Activities Report & Appendix 4C  
 
14 Oct 2020    Cover Letter and Proxy Form - Annual General Meeting  
 
14 Oct 2020    Notice of Annual General Meeting and Proxy Form  
 
12 Oct 2020    LuPIN Study Achieves Final Patient Treatment  
 
9 Oct 2020    Noxopharm CMO Discusses the NOXCOVID trial  
 
9 Oct 2020    Unlisted Options Expiring 27 November 2020  
 
9 Oct 2020    Cleansing Notice  
 
9 Oct 2020    Appendix 2A  
 
6 Oct 2020    Noxopharm Loan Terms Amended to Benefit Company  
 
2 Oct 2020    First COVID-19 Patient Treated in Veyonda Study  
 
21 Sep 2020    Noxopharm Corporate Presentation September 2020  
 
18 Sep 2020    Noxopharm Appoints US Corporate Advisory and Consulting Firm  
 
17 Sep 2020    Notification of Date of 2020 Annual General Meeting  
 
15 Sep 2020    Annual Report to shareholders  
 
15 Sep 2020    Appendix 4G and Corporate Governance Statement  
 
9 Sep 2020    Noxopharm Appoints New Chair  
 
8 Sep 2020    Global CRO To Execute DARRT-2 Prostate Cancer Study  
 
1 Sep 2020    Veyonda COVID-19 Study Approved For Immediate Start  
 
31 Aug 2020    Final Director's Interest Notice - ID  
 
31 Aug 2020    Appendix 4E and Audited Financial Statements FY2020  
 
31 Aug 2020    Appendix 4G and Corporate Governance Statement  
 
31 Aug 2020    Noxopharm Announces Board Changes  
 
14 Aug 2020    Appendix 2A - Shares  
 
14 Aug 2020    Cleansing Notice  
 
14 Aug 2020    Appendix 2A - Underwriter Options  
 
14 Aug 2020    Results of Meeting  
 
14 Aug 2020    Noxopharm August 2020 EGM Corporate Presentation  
 
11 Aug 2020    Peer-Reviewed Publication Strengthens Case For Veyonda  
 
6 Aug 2020    Noxopharm Extraordinary General Meeting Reminder  
 
29 Jul 2020    Noxopharm June 2020 Quarterly Activities Report & Appendix 4C  
 
24 Jul 2020    Change of Director's Interest Notice - FB  
 
24 Jul 2020    Notice of Contravention of Listing Rule 10.11  
 
23 Jul 2020    Noxopharm Discusses Converting Cold to Hot Cancer Tumours  
 
22 Jul 2020    Receipt of cash payment for collateral shares  
 
20 Jul 2020    Data Shows Idronoxil Holds Key to Problem of COLD Cancers  
 
14 Jul 2020    Noxopharm July 2020 Newsletter Released  
 
14 Jul 2020    Letter to Shareholders - Extraordinary General Meeting  
 
14 Jul 2020    Notice of Extraordinary General Meeting/Proxy Form  
 
8 Jul 2020    Corporate Presentation for the Reach Markets Virtual Event  
 
3 Jul 2020    Ceasing to be a substantial holder  
 
29 Jun 2020    Change of Director's Interest Notice - FB  
 
22 Jun 2020    Change in substantial holding - amended  
 
22 Jun 2020    Change in substantial holding  
 
22 Jun 2020    Noxopharm Chair Letter to Shareholders  
 
19 Jun 2020    COVID-19 Trial Program to Commence in Europe  
 
18 Jun 2020    Change in substantial holding  
 
18 Jun 2020    Change in substantial holding  
 
18 Jun 2020    Change of Director's Interest Notice - BP  
 
18 Jun 2020    Change of Director's Interest Notice - FB  
 
18 Jun 2020    Change of Director's Interest Notice - PM  
 
18 Jun 2020    Change of Director's Interest Notice - GK  
 
18 Jun 2020    Appendix 2A - shares  
 
18 Jun 2020    Appendix 2A - options  
 
15 Jun 2020    Pro-rata Non-Renounceable Rights Issue Fully Allocated  
 
9 Jun 2020    Rights Issue Close Date  
 
5 Jun 2020    Webcast Overview of ASCO 2020 Annual Meeting NOX Posters  
 
4 Jun 2020    Change of Director's Interest Notice - PM  
 
4 Jun 2020    Change of Director's Interest Notice - ID  
 
1 Jun 2020    Appendix 3G Adjustment to Option Exercise Prices  
 
1 Jun 2020    ASCO 2020 Highlights NOX66 Potential in Late-Stage Cancer  
 
28 May 2020    Listing Rule 6.22.2 Adjustment to Option Exercise Prices  
 
22 May 2020    Proposed issue of Securities - NOX  
 
21 May 2020    Despatch of Pro Rata Entitlement Offer Documents  
 
19 May 2020    FDA allows Veyonda Pre-IND Submission for COVID-19  
 
14 May 2020    Noxopharm ASCO Abstracts Live  
 
13 May 2020    Appendix 2A  
 
13 May 2020    Entitlement Offer Prospectus  
 
13 May 2020    Entitlement Offer - Letter to Optionholders  
 
13 May 2020    Entitlement Offer - Letter to Ineligible Shareholders  
 
13 May 2020    Entitlement Offer - Letter to Eligible Shareholders  
 
13 May 2020    Proposed issue of Securities - NOX  
 
13 May 2020    $7.9 Million Fully Underwritten Entitlement Offer Announced  
 
8 May 2020    Initial Director's Interest Notice - FB  
 
8 May 2020    Appointment of New Board Member  
 
7 May 2020    Trading Halt  
 
1 May 2020    Change in substantial holding  
 
1 May 2020    Change in substantial holding  
 
30 Apr 2020    Noxopharm March 2020 Quarterly Report & Appendix 4C  
 
30 Apr 2020    Abscopal Responses Achieved in Prostate Cancer  
 
23 Apr 2020    Pipeline Expands With Potential New Brain Cancer Treatment  
 
21 Apr 2020    Approval to be sought for COVID-19 Clinical Study in U.S.  
 
20 Apr 2020    Receipt of cash payment for collateral shares  
 
7 Apr 2020    Noxopharm trial data to be presented at ASCO 2020  
 
2 Apr 2020    Updated Noxopharm Virtual Roadshow Corporate Presentation  
 
1 Apr 2020    Noxopharm Investigating Potential COVID-19 Treatment  
 
31 Mar 2020    Noxopharm Virtual Roadshow Corporate Presentation  
 
26 Mar 2020    Initial Director's Interest Notice  
 
26 Mar 2020    Appointment of New Board Member  
 
17 Mar 2020    Veyonda Awarded First Allowed Patent Application  
 
13 Mar 2020    Veyonda Clinical Program Update and Guidance  
 
3 Mar 2020    LuPIN Prostate Cancer Trial Fully Recruited  
 
27 Feb 2020    Noxopharm Corporate Presentation February 2020  
 
25 Feb 2020    Half Year Accounts and Chairman Letter  
 
21 Feb 2020    Section 708 Certificate  
 
21 Feb 2020    Appendix 2A  
 
21 Feb 2020    FDA grants IND approval to Veyonda  
 
18 Feb 2020    Termination of Convertible Loan  
 
18 Feb 2020    Section 708 Certificate  
 
18 Feb 2020    Appendix 2A  
 
18 Feb 2020    Noxopharm Alliance With GenesisCare  
 
14 Feb 2020    Proposed issue of Securities - NOX  
 
14 Feb 2020    $8.1M Financing & Re-Set of Capital Structure  
 
14 Feb 2020    Pronounced survival benefit in LuPIN interim trial data  
 
12 Feb 2020    Trading Halt  
 
11 Feb 2020    LuPIN interim trial data to be presented at ASCO GU 2020  
 
6 Feb 2020    Lapsing of Unlisted Options  
 
31 Jan 2020    Noxopharm December 2019 Quarterly Activities Report & Appendix 4C  
 
29 Jan 2020    Noxopharm Non-Deal Roadshow Presentation  
 
20 Jan 2020    Appendix 3B  
 
16 Jan 2020    Listing of Nyrada Inc. spin-off on ASX  
 
16 Jan 2020    Becoming a substantial holder for NYR  
 
15 Jan 2020    Noxopharm Corporate Presentation  
 
27 Dec 2019    Ceasing to be a substantial holder  
 
23 Dec 2019    Change of Director's Interest Notice - GK  
 
23 Dec 2019    Section 708 Certificate  
 
23 Dec 2019    Appendix 3B  
 
20 Dec 2019    DARRT-1 Clinical Data Webinar  
 
17 Dec 2019    Nyrada IPO Offer Fully Subscribed  
 
13 Dec 2019    Unlisted Options Expiring 18 January 2020  
 
9 Dec 2019    Lodgement of Nyrada Inc Supplementary Prospectus  
 
4 Dec 2019    Nyrada Inc Initial Public Offering Opens  
 
3 Dec 2019    Section 708 Certificate - Notes  
 
3 Dec 2019    Section 708 Certificate  
 
3 Dec 2019    Appendix 3B  
 
3 Dec 2019    AU$2.4m Increase to Funding Agreement  
 
3 Dec 2019    Section 708 Certificate  
 
3 Dec 2019    Appendix 3B  
 
2 Dec 2019    Positive DARRT-1 Data in Late-Stage Prostate Cancer  
 
28 Nov 2019    Trading Halt  
 
26 Nov 2019    Lodgement of Nyrada Inc Prospectus - Initial Public Offering  
 
26 Nov 2019    Lodgement of Nyrada Inc Prospectus - Initial Public Offering - Interactive  
 
20 Nov 2019    Constitution  
 
20 Nov 2019    Results of Meeting  
 
20 Nov 2019    Noxopharm 2019 AGM Corporate Presentations  
 
12 Nov 2019    DARRT-1 Interim Data Presented To Conference  
 
12 Nov 2019    LuPIN Data Being Presented To Conference  
 
6 Nov 2019    Appointment of Chief Commercial Officer  
 
30 Oct 2019    Noxopharm October 2019 Newsletter  
 
30 Oct 2019    Appendix 4C - Quarterly Report for The Quarter Ending September 30, 2019  
 
28 Oct 2019    Dr Graham Kelly to Assume CEO Role  
 
25 Oct 2019    Appendix 3B  
 
25 Oct 2019    Section 708 Certificate  
 
22 Oct 2019    NOX and Nyrada TechKnow Invest Roadshow Presentations  
 
21 Oct 2019    Durable Anti-Cancer Effect Confirmed in DARRT-1 Study  
 
18 Oct 2019    Notice of 2019 Annual General Meeting & Proxy Form  
 
18 Oct 2019    Potential Fundamental Change in Treatment of Brain Cancer  
 
16 Oct 2019    New Executive Appointments and Board Change  
 
16 Oct 2019    Final Director's Interest Notice  
 
2 Oct 2019    Noxopharm 2019 Annual General Meeting Details  
 
2 Oct 2019    FNN Interview: The LuPIN trial with Veyonda in prostate cancer  
 
30 Sep 2019    Further Review Shows Major Clinical Benefits from Veyonda  
 
26 Sep 2019    Corporate Governance Statement - Appendix 4G  
 
26 Sep 2019    Corporate Governance Statement  
 
26 Sep 2019    Section 708 Certificate  
 
26 Sep 2019    Appendix 3B  
 
26 Sep 2019    Noxopharm 2019 Annual Report  
 
24 Sep 2019    Departure of Dr Van Wyk  
 
17 Sep 2019    Veyonda and Radiotherapy Profiled at Key Oncology Meeting  
 
16 Sep 2019    Results of Meeting  
 
16 Sep 2019    NOX EGM Chairman's Address and Presentation  
 
12 Sep 2019    CHANGE OF DIRECTOR'S INTEREST NOTICE - GK  
 
10 Sep 2019    CHANGE OF DIRECTOR'S INTEREST NOTICE - GK  
 
29 Aug 2019    Appendix 4E and Audited Financial Statements FY19  
 
28 Aug 2019    Addendum to Notice of Extraordinary General Meeting  
 
28 Aug 2019    More Evidence that Veyonda Enhances RT in Prostate Cancer  
 
23 Aug 2019    NOX Receives FY19 Federal Government R&D Tax Rebate  
 
23 Aug 2019    Appendix 3B  
 
23 Aug 2019    Cleansing Statement  
 
21 Aug 2019    Pre-Clinical Evidence Confirms Veyonda Abscopal Effect  
 
15 Aug 2019    Lead Manager Appointed for Proposed Nyrada IPO  
 
12 Aug 2019    Notice of Extraordinary General Meeting/Proxy Form  
 
9 Aug 2019    Noxopharm Corporate Update Interview  
 
7 Aug 2019    Noxopharm August 2019 Corporate Presentation  
 
2 Aug 2019    NOX Releases Initial Newsletter for Nyrada Subsidiary  
 
29 Jul 2019    Appendix 4C - Quarterly Report for the quarter ending June 30, 2019  
 
25 Jul 2019    Appendix 3B  
 
25 Jul 2019    Section 708 Certificate  
 
23 Jul 2019    Appendix 3B  
 
23 Jul 2019    Section 708 Certificate  
 
19 Jul 2019    Initial Director's Interest Notice  
 
19 Jul 2019    Final Director's Interest Notice  
 
19 Jul 2019    NOX Announces AU$26 Million Funding Facility  
 
17 Jul 2019    NOX Releases Latest Newsletter  
 
16 Jul 2019    Board Changes Ahead of Corporate Growth  
 
2 Jul 2019    LuPIN-1 Interim Results Presentation Recording at SNMMI Annual Meeting 2019  
 
26 Jun 2019    Conference Hears of Positive Interim Data from LuPIN Trial  
 
7 Jun 2019    NOX Subsidiary, Nyrada Inc, Receives R&D Rebate  
 
6 Jun 2019    Noxopharm Corporate Presentation June 2019  
 
30 May 2019    DARRT-1 Study Fully Enrolled  
 
23 May 2019    Promising Data Leads to Expansion of LuPIN Trial  
 
20 May 2019    LuPIN Trial Demonstrates High Rates of Response  
 
8 May 2019    Change of Director's Interest Notice - GK  
 
8 May 2019    Appendix 3B  
 
2 May 2019    DARRT Treatment Has Lasting Disease Control at Six Months  
 
29 Apr 2019    Veyonda and Immuno-Oncology Effect Explained  
 
26 Apr 2019    Appendix 4C - Quarterly  
 
23 Apr 2019    Change in Noxopharm Limited Board Structure  
 
16 Apr 2019    Idronoxil Confirmed as New Immuno-Oncology Drug  
 
10 Apr 2019    Veyonda Chemotherapy Enhancement Program to be Expanded  
 
8 Apr 2019    Securities to be released from Voluntary Escrow  
 
5 Apr 2019    Updated Top 20 shareholder List  
 
25 Mar 2019    Appendix 3B  
 
25 Mar 2019    Section 708 Certificate  
 
21 Mar 2019    Becoming a substantial holder  
 
19 Mar 2019    KZA: Kazia sells stake in Noxopharm  
 
6 Mar 2019    NOX provides update to Nyrada Note Holders  
 
5 Mar 2019    New Corporate Presentation Released  
 
21 Feb 2019    Noxopharm to expedite Veyonda Clinical Program  
 
21 Feb 2019    Appendix 4D and Half Year Accounts  
 
14 Feb 2019    Change of Director's Interest Notice - GK  
 
6 Feb 2019    FNN interview with Nox Chief Medical Officer on Interim Data  
 
6 Feb 2019    Veyonda and Radiotherapy Delivers Clinical Benefits  
 
1 Feb 2019    Appendix 3B  
 
29 Jan 2019    Appendix 4C - quarterly report for the quarter ended December 31, 2018  
 
14 Jan 2019    Principal Investigator Discusses LuPIN-1 Study  
 
21 Dec 2018    Change of Director's Interest Notice - GK  
 
21 Dec 2018    Section 708 Certificate  
 
21 Dec 2018    Appendix 3B  
 
20 Dec 2018    NOX Receives $3.26M Federal Govt R&D Rebate  
 
11 Dec 2018    DARRT-1 study advancing on basis of positive clinical data  
 
29 Nov 2018    NOX announces Positive Data from CEP-1 Study of Veyonda  
 
21 Nov 2018    Initial Director's Interest Notice  
 
21 Nov 2018    Results of Meeting  
 
21 Nov 2018    Appointment of Mr John Moore as Non-Executive Director  
 
21 Nov 2018    NOX 2018 AGM Presentations  
 
20 Nov 2018    NOX 2018 AGM Information  
 
13 Nov 2018    NOX to Present Clinical Data at COSA Annual Meeting  
 
8 Nov 2018    Corporate Presentation  
 
26 Oct 2018    Appendix 4C - Quarterly report for the quarter ended September 30, 2018  
 
22 Oct 2018    NOX makes key executive appointment  
 
5 Oct 2018    Notice of Annual General Meeting & Proxy Form  
 
4 Oct 2018    Noxopharm Releases Report on Key Progress of Subsidiary  
 
2 Oct 2018    Section 708 Certificate  
 
2 Oct 2018    Appendix 3B  
 
28 Sep 2018    Change of Director's Interest Notice - PM  
 
28 Sep 2018    Section 708 Certificate  
 
28 Sep 2018    Appendix 3B  
 
28 Sep 2018    Change of Registry Address: Automic P/L - Sydney Office  
 
27 Sep 2018    Annual Report to shareholders  
 
27 Sep 2018    Corporate Governance Statement - Appendix 4G  
 
27 Sep 2018    Corporate Governance Statement - 2018  
 
24 Sep 2018    NOX Subsidiary Announces Important Drug Discovery  
 
5 Sep 2018    NOX to support expanded LuPIN study  
 
30 Aug 2018    Appendix 4E and Audited Financial Statements  
 
27 Aug 2018    Nyrada-Key progress with cholesterol-lowering drug candidate  
 
20 Aug 2018    VEYONDA - Registered Trade Mark for NOX66  
 
9 Aug 2018    Change of Director's Interest Notice - GK  
 
9 Aug 2018    Change of Director's Interest Notice - PM  
 
9 Aug 2018    Change of Director's Interest Notice - ID  
 
9 Aug 2018    Appendix 3B  
 
8 Aug 2018    Interim NOX66 Radiotherapy Clinical Data  
 
30 Jul 2018    Appendix 4C- Quarterly report for the quarter ended June 30, 2018  
 
10 Jul 2018    Securities to be released from Escrow  
 
9 Jul 2018    Release of DARRT-1 Preliminary Safety Data  
 
5 Jul 2018    Pre-Clinical data confirms Radio-Enhancing potential  
 
7 Jun 2018    Noxopharm Corporate Presentation for Public Briefing  
 
5 Jun 2018    End-of-Study Clinical Data shows benefit of NOX66  
 
31 May 2018    Noxopharm 2018 Mid-Year Investor Briefings  
 
28 May 2018    Section 708 Certificate  
 
28 May 2018    Appendix 3B  
 
22 May 2018    NOX to present at American Society of Clinical Oncology  
 
21 May 2018    Change in substantial holding  
 
21 May 2018    Securities to be released from Voluntary Escrow  
 
21 May 2018    Section 708 Certificate  
 
21 May 2018    Appendix 3B  
 
18 May 2018    Noxopharm 2018 Mid-Year Investor Briefings  
 
15 May 2018    Results of Meeting  
 
7 May 2018    NOX CEO interview updates the company's current R&D program  
 
3 May 2018    NOX CEO interview on near complete NOX66 chemotherapy trial  
 
27 Apr 2018    NOX CEO interview on Radiotherapy Clinical Programs  
 
27 Apr 2018    Appendix 4C - quarterly  
 
17 Apr 2018    St Vincent's Hospital study passes first milestone  
 
9 Apr 2018    Notice of Extraordinary General Meeting / Proxy Form  
 
6 Apr 2018    Change in substantial holding  
 
6 Apr 2018    Change in substantial holding  
 
5 Apr 2018    DARRT-1 Clinical Study commences  
 
5 Apr 2018    NOX Mid-Year Briefings  
 
29 Mar 2018    Section 708 Certificate  
 
29 Mar 2018    Appendix 3B  
 
23 Mar 2018    NOX raises $10.8 M to advance clinical program  
 
21 Mar 2018    Trading Halt  
 
21 Mar 2018    Evidence of Abscopal Responses in Patients  
 
12 Mar 2018    Corporate Presentation - Post Interim Clinical Data Release  
 
9 Mar 2018    FNN Interview with Noxopharm CEO  
 
6 Mar 2018    NOX Reports NOX66 Clinical Data  
 
5 Mar 2018    Trading Halt  
 
23 Feb 2018    Update accompanying Half Year Report  
 
23 Feb 2018    Appendix 4D and Half Year Accounts  
 
16 Feb 2018    NOX closes $4m capital raising for US subsidiary Nyrada Inc  
 
31 Jan 2018    Appendix 4C - quarterly  
 
25 Jan 2018    Section 708 Certificate  
 
25 Jan 2018    Appendix 3B  
 
18 Jan 2018    Section 708 Certificate  
 
18 Jan 2018    Appendix 3B  
 
17 Jan 2018    NOX receives FY17 R&D Tax Rebate  
 
27 Dec 2017    Kazia Therapeutics Ltd and Noxopharm Ltd  
 
21 Dec 2017    EOY Guidance on 2018 NOX66 Clinical Development Strategy  
 
19 Dec 2017    Section 708 Certificate  
 
19 Dec 2017    Appendix 3B  
 
14 Dec 2017    Response to ASX Price Query  
 
12 Dec 2017    Appendix 3B  
 
11 Dec 2017    Change of Registered Office  
 
7 Dec 2017    Section 708 Certificate  
 
7 Dec 2017    Appendix 3B  
 
6 Dec 2017    NOX Open Briefing Corporate Presentation  
 
4 Dec 2017    Compassionate use of NOX66 in Patients  
 
1 Dec 2017    Nyrada Inc Opens Capital Raise - Memorandum Released  
 
29 Nov 2017    Change of Director's Interest Notice - PM  
 
29 Nov 2017    Change of Director's Interest Notice - ID  
 
29 Nov 2017    Appendix 3B  
 
29 Nov 2017    Webcast of NOX 2017 AGM  
 
29 Nov 2017    NYX-104 delivers Key Proof-of-Concept in Stroke Animal Model  
 
28 Nov 2017    Invitation to Open Briefing  
 
27 Nov 2017    Results of Meeting  
 
27 Nov 2017    AGM Presentations  
 
23 Nov 2017    Clarification of Incorrect Information  
 
23 Nov 2017    Trading Halt  
 
21 Nov 2017    NOX 2017 AGM Webcast  
 
21 Nov 2017    Completion of Transfer of Shares to Nyrada Inc  
 
20 Nov 2017    Promising Interim Clinical Data for NOX66  
 
17 Nov 2017    Trading Halt  
 
16 Nov 2017    1st Patient treated in Lupin Study at St Vincent's Hospital  
 
15 Nov 2017    Section 708 Certificate  
 
15 Nov 2017    Appendix 3B  
 
13 Nov 2017    NOX making three presentations at COSA  
 
7 Nov 2017    Section 708 Certificate  
 
7 Nov 2017    Appendix 3B  
 
6 Nov 2017    Results of Meeting  
 
6 Nov 2017    EGM Presentations  
 
3 Nov 2017    UNSW collaboration confirms drug designed for stroke victims  
 
30 Oct 2017    Appendix 4C – Quarterly report for the quarter ended September 30, 2017  
 
26 Oct 2017    Notice of Annual General Meeting/Proxy Form  
 
26 Oct 2017    Noxopharm 2017 Annual Report  
 
23 Oct 2017    Update - General Meeting Agenda  
 
19 Oct 2017    October 2017 Open Briefing Corporate Presentation  
 
13 Oct 2017    Invitation to Open Briefing  
 
4 Oct 2017    Establishment of Nyrada Inc. - Extraordinary General Meeting  
 
27 Sep 2017    Australian NOX66 - Radiotherapy Study Opens  
 
25 Sep 2017    Establishment of Nyrada Inc.  
 
12 Sep 2017    Positive Clinical Outcomes for NOX66 at ESMO Conference  
 
7 Sep 2017    Change in substantial holding  
 
6 Sep 2017    Change in substantial holding  
 
4 Sep 2017    Placement completed App 3B, s708 Notice, LR7.1A4(b) Notice  
 
4 Sep 2017    NOX CEO Interview explains recent Brain Cancer Announcement  
 
31 Aug 2017    Appendix 4E and Audited Financial Statements  
 
31 Aug 2017    Corporate Governance Statement - Appendix 4G  
 
31 Aug 2017    Corporate Governance Statement  
 
29 Aug 2017    Important Brain Cancer Findings for NOX66 Program  
 
24 Aug 2017    Reinstatement to Official Quotation  
 
24 Aug 2017    Noxopharm raises $5.5 million to advance clinical program  
 
23 Aug 2017    Suspension from Official Quotation  
 
21 Aug 2017    Trading Halt Request  
 
21 Aug 2017    Trading Halt  
 
8 Aug 2017    NOX Corporate Presentation ahead of Conference  
 
31 Jul 2017    Appendix 4C - quarterly  
 
27 Jul 2017    NOX Research Report prepared by APP Securities  
 
25 Jul 2017    CEO Interview with FNN - Singapore and HK Roadshow  
 
25 Jul 2017    New Corporate Presentation  
 
6 Jul 2017    Noxopharm provides update on NOX66 Clinical Trial Program  
 
19 Jun 2017    Idronoxil data provides hope to treat secondary brain cancer  
 
5 Jun 2017    NOX66 confirmed Non-Toxic. Trial Cleared for Full Enrolment  
 
30 May 2017    New Corporate Presentation  
 
29 May 2017    St Vincents Cancer Study to Commence-NOX66 and Radiotherapy  
 
24 May 2017    NOX makes strategic commitment to treatment of rare cancers  
 
18 May 2017    Noxopharm Mid Year Investor Briefings  
 
2 May 2017    Market Guidance for Next Six Months  
 
27 Apr 2017    Appendix 4C - quarterly  
 
10 Apr 2017    FNN Interview with NOX CEO Explaining Idronoxil-C Discovery  
 
10 Apr 2017    NOX Files Patent Application on 'Smart' Idronoxil  
 
3 Apr 2017    Appendix 3B  
 
27 Mar 2017    NOX and Monash Uni Collaboration Receives Federal Grant  
 
16 Mar 2017    Noxopharm and UNSW combine on stroke project  
 
10 Mar 2017    Gold Coast Qld Mid-Year Briefing Details  
 
7 Mar 2017    Notification of Release of Restricted Securities Escrow  
 
3 Mar 2017    NOX researching rare Abscopal Response  
 
24 Feb 2017    Appendix 4D and Half Year Accounts  
 
24 Feb 2017    NOX Presentation and Interview ASX The CEO Sessions  
 
21 Feb 2017    ASX CEO Presentation Feb 2017 slides  
 
15 Feb 2017    Upcoming Events and Presentations  
 
3 Feb 2017    Change of Principal Place of Business  
 
1 Feb 2017    Brain Cancer Study Commences  
 
31 Jan 2017    First NOX66 Clinical Trial to Commence  
 
30 Jan 2017    Appendix 4C – Quarterly report for the quarter ended 31 December 2016  
 
16 Jan 2017    Appointment of New Company Secretary  
 
9 Jan 2017    Appendix 3B  
 
20 Dec 2016    Change in substantial holding  
 
20 Dec 2016    Change of Director's Interest Notice - ID  
 
20 Dec 2016    Change of Director's Interest Notice - GK  
 
20 Dec 2016    Market Capitalisation - further update  
 
20 Dec 2016    Appendix 3B  
 
19 Dec 2016    Market Capitalisation Update  
 
23 Nov 2016    Results of Meeting  
 
23 Nov 2016    Breakthrough in Delivering Idronoxil into Brain  
 
22 Nov 2016    Corporate Presentation Updated  
 
22 Nov 2016    Corporate Presentation Providing Clinical Program Guidance  
 
17 Nov 2016    Medical Advisors Appointed for Extensive Clinical Program  
 
14 Nov 2016    Change in substantial holding DH  
 
31 Oct 2016    Appendix 4C - quarterly  
 
24 Oct 2016    Noxopharm 2016 AGM Sydney Briefing  
 
21 Oct 2016    Noxopharm 2016 Annual Report  
 
20 Oct 2016    Corporate Presentation  
 
3 Oct 2016    Appendix 4G  
 
30 Sep 2016    Amendment to Preliminary Final Report  
 
12 Sep 2016    Corporate Presentation for Roadshow  
 
31 Aug 2016    Preliminary Final Report  
 
25 Aug 2016    Change in substantial holding  
 
22 Aug 2016    Change in substantial holding DH  
 
22 Aug 2016    Noxopharm to Initiate Radiotherapy Clinical Studies  
 
19 Aug 2016    Change of Director's Interest Notice - GK  
 
10 Aug 2016    Becoming a substantial holder  
 
10 Aug 2016    Becoming a substantial holder  
 
10 Aug 2016    Becoming a substantial holder  
 
10 Aug 2016    Initial Director's Interest Notice - PM  
 
10 Aug 2016    Initial Director's Interest Notice - ID  
 
10 Aug 2016    Initial Director's Interest Notice - GK  
 
9 Aug 2016    Noxopharm Limited commences trading on ASX  
 
8 Aug 2016    Performance Share Terms  
 
8 Aug 2016    Option Terms  
 
8 Aug 2016    Restricted Securities and Capital Structure  
 
8 Aug 2016    Securities Trading Policy  
 
8 Aug 2016    Financial Accounts  
 
8 Aug 2016    Constitution  
 
8 Aug 2016    ASX Market Release - Admission to Official List  
 
8 Aug 2016    Appendix 1A & Information Form and Checklist  
 
8 Aug 2016    Top 20 Holders  
 
8 Aug 2016    Distribution Schedule  
 
8 Aug 2016    Company's Admission Disclosures